Met tyrosine kinase receptor, also known as c-Met, is the HGF (hepatocyte growth factor)
receptor. The HGF/Met pathway has a prominent role in cardiovascular remodelling after …

Rationale: Umbilical cord–derived mesenchymal stem cells (UC-MSC) are easily accessible
and expanded in vitro, possess distinct properties, and improve myocardial remodeling and …

Current pharmacologic therapy for ischemic heart disease suffers multiple limitations such
as compliance issues and side effects of medications. Revascularization procedures often …

Therapeutic neovascularization for cardiovascular ischemia is a promising avenue in spite
of disappointing early clinical trial results. The concept of three different mechanisms of …

Introduction: Cardiovascular gene therapy is the third most popular application for gene
therapy, representing 8.4% of all gene therapy trials as reported in 2012 estimates. Gene …

Hepatocyte growth factor (HGF) is a cytokine whose multipotent actions are mediated by c-
Met receptor. This review focuses on effects of HGF on myocardial infarction (MI) and heart …

Objective Therapeutic angiogenesis is a new strategy for treatment of vascular insufficiency.
Hepatocyte growth factor (HGF)-induced angiogenesis has been applied to induce the …

Background: Myocardial infarction (MI) is the most severe ischemic heart disease and
directly leads to heart failure till death. Target molecules have been identified in the event of …

Myocardial infarction (MI) is a leading cause of hospitalization worldwide. A recently
developed strategy to improve the management of MI is based on the use of growth factors …

Hepatocyte growth factor (HGF) has been shown to induce angiogenesis in vivo and has
potential as a candidate gene for 'therapeutic angiogenesis'. In vivo, two isoforms of HGF …